# 510(k) Summary

As required by 21 CFR Section 807.92(c).

Submitted by:

Cepheid® 904 Caribbean Drive Sunnyvale, CA 90489 Phone number: (408) 400-8460. Fax number: (408) 541-6439

Contact:

Date of Preparation:

Russel K. Enns, Ph.D. April 22, 2011

Device:

Xpert Flu

Trade name: Common name: Type of Test:

Xpert Flu Assay

Automated, multiplex real-time reverse transcriptionpolymerase chain reaction (rRT-PCR) assay intended for the in vitro qualitative detection and differentiation of influenza A, influenza B and 2009 H1N1 influenza viral RNA.

Regulation number/ Classification name:

866.3980/Respiratory viral panel multiplex nucleic acid assay

OQW, OCC, 001

Product code: Classification Advisory Panel

Microbiology (83)

Predicate Devices:

K073029: ProFLU ${ \bf + T M }$ Assay,   
Gen-Probe Prodesse, Inc.   
K100148: SimplexaTM Influenza A H1N1(2009), Focus Diagnostics, Inc.

# Device Description:

The Xpert Flu Assay is a rapid, automated in vitro diagnostic test for qualitative detection and differentiation of influenza A, influenza B and influenza A, subtype 2009 H1N1. The assay is performed on the Cepheid GeneXpert Instrument Systems. The GeneXpert Instrument Systems automate and integrate sample purification, nucleic acid amplification, and detection of the target sequence in simple or complex samples using real-time PCR and RT-PCR assays. The systems require the use of single-use disposable cartridges that hold the PCR reagents and host the PCR process. Because the cartridges are self-contained and specimens never come into contact with working parts of the instrument modules, cross-contamination between samples is eliminated.

The Xpert Flu Assay includes reagents for the detection and differentiation of influenza A, influenza B and influenza A, subtype 2009 H1N1 directly from nasal aspirates/washes (NA/W) and nasopharyngeal (NP) swab specimens from patients with signs and symptoms of respiratory infection. A Sample Processing Control (SPC) and a Probe Check Control (PCC) are also included. The SPC is present to control for adequate processing of the target viruses and to monitor the presence of inhibitors in the PCR reaction. The Probe Check Control (PCC) verifies reagent rehydration, PCR tube filling in the cartridge, probe integrity and dye stability.'

The liquid specimen (NA/W) or swab specimen (NP) is collected according to the institution's standard procedures and placed into Universal Transport Medium ( $3 \mathrm { m L }$ UTM tubes). Following a brief mixing by inverting the UTM tube five times, the eluted material and one single-use reagent (Reagent 1), that is provided with the assay, are transferred to different, uniquely-labeled chambers of the disposable fluidic cartridge (the Xpert Flu cartridge). The user initiates a test from the system user interface and places the cartridge into the GeneXpert instrument platform, which performs hands-off reverse transcription and real-time, multiplex polymerase chain reaction (PCR) for detection of DNA. In this platform, additional sample preparation, amplification, and real-time detection are all fully-automated and completely integrated.

The single-use, multi-chambered fluidic cartridges are designed to complete sample preparation and real-time RT-PCR for detection and differentiation of influenza A, influenza B and influenza A, subtype 2009 H1N1 in 75 minutes. The GeneXpert Instrument Systems have 1 to 48 randomly accessible modules that are each capable of performing separate sample preparation and real-time PCR tests. Each module contains a syringe drive for dispensing fluids (i.e., the syringe drive activates the plunger that works in concert with the rotary valve in the cartridge to move fluids between chambers), an ultrasonic horn for lysing cells or spores, and a proprietary I-CORE $\textsuperscript { \textregistered }$ thermocycler for performing real-time PCR and detection.

# Device Intended Use:

The Cepheid $\textsuperscript { \textregistered }$ Xpert Flu Assay is an automated, multiplex real-time RT-PCR assay intended for the in vitro qualitative detection and differentiation of influenza A, influenza B and 2009 H1N1 influenza viral RNA. The Xpert Flu Assay uses nasal aspirates/washes and nasopharyngeal swab specimens collected from patients with signs and symptoms of respiratory infection in conjunction with clinical and epidemiological risk factors. The Xpert Flu Assay is intended as an aid in the diagnosis of influenza.

Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other patient management decisions.

Performance characteristics for influenza A were established during the 2009-2010 influenza season when 2009 H1N1 influenza was the predominant influenza A virus in circulation. When other influenza A viruses are emerging, performance characteristics may vary.

# CONFIDENTIAL

If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infeotion control precautions for novel virulent influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL $^ { 3 + }$ facility is available to receive and culture specimens.

# Substantial Equivalence:

The Xpert Flu Assay is substantially equivalent to the following predicate assays:

K073029: ProFLU $+ \mathbf { T M }$ Assay, Gen-Probe Prodesse, Inc.   
K100148: Simplexa™M Influenza A H1N1(2009), Focus Diagnostics, Inc.

Similarities and differences between the Cepheid Xpert Flu Assay and the predicate devices are shown in Table 5.1.

A clinical study at six sites was conducted to compare Xpert Flu Assay performance to the standard of care, viral culture followed by direct fluorescent assay (DFA). Sequencing for all influenza A positive specimens. For archived specimens, where viral culture was not performed prior to freezing, a FDA cleared molecular assay was performed as the comparator assay followed by sequencing of all influenza A positive specimens.

Table 5.1: Comparison of Similarities and Differences of the Xpert Flu Assay with the Predicate Devices   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=2>Predicates</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Cepheid Xpert Flu</td><td rowspan=1 colspan=1>Gen-Probe Prodesse,Inc. ProFLU+</td><td rowspan=1 colspan=1>Focus SimplexaInfluenza A H1N1</td></tr><tr><td rowspan=1 colspan=1>510(k) No.</td><td rowspan=1 colspan=1>K103766</td><td rowspan=1 colspan=1>K073029</td><td rowspan=1 colspan=1>K100148</td></tr><tr><td rowspan=1 colspan=1>Regulation</td><td rowspan=1 colspan=1>866.3332 and 866.3980</td><td rowspan=1 colspan=1>866.3980</td><td rowspan=1 colspan=1>866.3332</td></tr><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>OQW, OCC, 001</td><td rowspan=1 colspan=1>OCC</td><td rowspan=1 colspan=1>OQW</td></tr><tr><td rowspan=1 colspan=1>Device Class</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>II</td></tr><tr><td rowspan=1 colspan=1>Technology/Detection</td><td rowspan=1 colspan=1>Multiplex real time RT/PCR</td><td rowspan=1 colspan=1>Multiplex real timeRT/PCR</td><td rowspan=1 colspan=1>Multiplex real timeRT/PCR</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>An automated, multiplexreal-time RT-PCR assayintended for the in vitroqualitative detection anddifferentiation of influenzaA, influenza B and 2009H1N1 influenza viral RNA.The Xpert Flu Assay usesnasal aspirates/washes andnasopharyngeal swab</td><td rowspan=1 colspan=1>A multiplex Real TimeRT-PCR in vitrodiagnostic test for therapid and qualitativedetection anddiscrimination ofInfluenza A Virus,Influenza B Virus, andRespiratory SyncytialVirus (RSV) nucleic</td><td rowspan=1 colspan=1>For use on the 3MIntegrated Cycler as part ofthe Microfluidic MolecularSystem for the in vitroqualitative detection anddifferentiation of influenzaA and 2009 H1N1influenza viral RNA innasopharyngeal swabs(NPS), nasal swabs (NS),</td></tr></table>

# CONFIDENTIAL

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=2>Predicates</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Cepheid Xpert Flu</td><td rowspan=1 colspan=1>Gen-Probe Prodesse,Inc. ProFLU+</td><td rowspan=1 colspan=1>Focus SimplexaInfluenza A H1N1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>specimens collected frompatients with signs andsymptoms of respiratoryinfection in conjunctionwith clinical andepidemiological risk factors.The Xpert Flu Assay isintended as an aid in thediagnosis of influenza.Negative results do notpreclude influenza virusinfection and should not beused as the sole basis fortreatment or other patientmanagement decisions.Performance characteristicsfor influenza A wereestablished during the 2009-2010 influenza season when2009 H1N1 influenza wasthe predominant influenzaA virus in circulation. Whenother influenza A virusesare emerging, performancecharacteristics may vary.If infection with a novelinfluenza A virus issuspected based on currentclinical and epidemiologicalscreening criteriarecommended by publichealth authorities,specimens should becollected with appropriateinfection controlprecautions for novelvirulent influenza virusesand sent to state or localhealth department fortesting. Viral culture shouldnot be attempted in thesecases unless a BSL 3+facility is available toreceive and culturespecimens.</td><td rowspan=1 colspan=1>acids isolated andpurified fromnasopharyngeal (NP)swab specimensobtained fromsymptomatic patients.This test is intended foruse to aid in thedifferential diagnosis ofInfluenza A, InfluenzaB and RSV2 viralinfections in humansand is not intended todetect Influenza C.A negative test ispresumptive and it isrecommended theseresults be confirmed bycell culture. Negativeresults do not precludeinfluenza or RSV virusinfection and shouldnot be used as the solebasis for treatment orother managementdecisions.</td><td rowspan=1 colspan=1>and nasopharyngealaspirates (NPA) fromhuman patients with signsand symptoms ofrespiratory infection inconjunction with clinicaland epidemiological riskfactors.Negative results do notpreclude influenza virusinfection and should not beused as the sole basis fortreatment or other patientmanagement decisions.Performance characteristicsfor influenza A wereestablished during the2009-2010 influenza seasonwhen 2009 H1N1 influenzawas the predominantinfluenza A virus incirculation. When otherInfluenza A viruses areemerging, performancecharacteristics may vary.If infection with a novelInfluenza A virus issuspected based on currentclinical andepidemiological screeningcriteria recommended bypublic health authorities,specimens should becollected with appropriateinfection controlprecautions for novelvirulent Influenza virusesand sent to state or localhealth department fortesting. Viral culture shouldnot be attempted in thesecases unless a BSL 3+facility is available toreceive and culturespecimens</td></tr></table>

# CONFIDENTIAL

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=2>Predicates</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Cepheid Xpert Flu</td><td rowspan=1 colspan=1>Gen-Probe Prodesse,Inc. ProFLU+</td><td rowspan=1 colspan=1>Focus SimplexaInfluenza A H1N1</td></tr><tr><td rowspan=1 colspan=1>Indication for Use</td><td rowspan=1 colspan=1>Patients with signs andsymptoms of respiratoryinfection in conjunctionwith clinical andepidemiological risk factors.</td><td rowspan=1 colspan=1>Symptomatic patients</td><td rowspan=1 colspan=1>Patients with signs andsymptoms of respiratoryinfection in conjunctionwith clinical andepidemiological risk factors</td></tr><tr><td rowspan=1 colspan=1>Assay Targets</td><td rowspan=1 colspan=1>Influenza A,influenza B, and influenzaA, subtype 2009 H1N1</td><td rowspan=1 colspan=1>Influenza A, influenzaB, RespiratorySyncytial Virus Type Aand Type B</td><td rowspan=1 colspan=1>Influenza A/2009 HIN1 influenza</td></tr><tr><td rowspan=1 colspan=1>Specimen Types</td><td rowspan=1 colspan=1>Nasal aspirates/washes(NA/W) andNasopharyngeal (NP) swabs</td><td rowspan=1 colspan=1>NP swab</td><td rowspan=1 colspan=1>NP swab, Nasal Swab (NS)and nasopharyngealaspirates (NA/W)</td></tr><tr><td rowspan=1 colspan=1>TechnologicalPrinciples</td><td rowspan=1 colspan=1>RT/PCR</td><td rowspan=1 colspan=1>RT/PCR</td><td rowspan=1 colspan=1>RT/PCR</td></tr><tr><td rowspan=1 colspan=1>Nucleic AcidExtraction</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>ExtractionMethods</td><td rowspan=1 colspan=1>Sample preparationintegrated in GeneXpertCartridge and GeneXpertInstrumentation System</td><td rowspan=1 colspan=1>Roche MagNA PureLC Total NA IsolationKit</td><td rowspan=1 colspan=1>Roche MagNA Pure LCTotal NA Isolation Kit,QIAGEN QIAamp ViralRNA mini Kit</td></tr><tr><td rowspan=1 colspan=1>Assay Results</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>Qualitative</td></tr><tr><td rowspan=1 colspan=1>Instrument System</td><td rowspan=1 colspan=1>Cepheid GeneXpertInstrument Systems</td><td rowspan=1 colspan=1>Cepheid Smartcycler®II</td><td rowspan=1 colspan=1>3M Integrated cycler</td></tr><tr><td rowspan=1 colspan=1>Assay Controls</td><td rowspan=1 colspan=1>Encapsulated (armored)RNA pseudovirus as asample processingcontrol.Available but notprovided are inactivatedvirus controls for Flu A/Band Flu A H1N1 asexternal positive controlsand Coxsackie virus as anexternal negative control.</td><td rowspan=1 colspan=1>Inf A RNA Control, InfB RNA Control, RSVA RNA Control, RSVB RNA Control and aninternal</td><td rowspan=1 colspan=1>Armored RNA InternalControl, No TemplateControl, and H1N1 PositiveControl provided</td></tr><tr><td rowspan=1 colspan=1>Test results</td><td rowspan=1 colspan=1>Total 75 minutes for samplepreparation andrRT-PCR</td><td rowspan=1 colspan=1>Total 205 minutes(~45 minutes forsample preparation~2.0 hours forrRT-PCR)</td><td rowspan=1 colspan=1>Total 115 minutes(~45 minutes for samplepreparation~70 minutes forrRT-PCR)</td></tr></table>

# CONFIDENTIAL

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=2>Predicates</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Cepheid Xpert Flu</td><td rowspan=1 colspan=1>Gen-Probe Prodesse,Inc. ProFLU+\</td><td rowspan=1 colspan=1>Focus SimplexaInfluenza A H1N1</td></tr><tr><td rowspan=1 colspan=1>Laboratory Users</td><td rowspan=1 colspan=1>CLIA Moderate to HighComplexity        I</td><td rowspan=1 colspan=1>CLIA High Complexity</td><td rowspan=1 colspan=1>CLIA High Complexity</td></tr></table>

Non-Clinical Studies:

# Analytical Sensitivity

# Analytical Reactivity (Inclusivity)

The analytical reactivity of the Xpert Flu Assay was evaluated against thirty-nine (39) strains of influenza A (H1N1, H3N2, H5N2, H5N1, and H7N3 subtypes), influenza A 2009 H1N1 and influenza B. Of these, influenza A subtype H1N1 (12), influenza A subtype H3N2 (7), influenza A subtype 2009 H1N1 (6), influenza A subtype H5N1 (1), influenza A subtype H5N2 (1), influenza A subtype H7N3 (1) and influenza B (11) were included. Three replicates of each viral strain were tested at $5 - 5 0 0 \mathrm { T C I D } _ { 5 0 } / \mathrm { m L }$ unless noted otherwise. Results are shown in Table 5.2.

Table 5.2: Analytical Reactivity (Inclusivity) of Xpert Flu Assay   

<table><tr><td rowspan=1 colspan=1>Viral Strain</td><td rowspan=1 colspan=1>Concentration(TCIDs/mL)</td><td rowspan=1 colspan=1>InfluenzaA</td><td rowspan=1 colspan=1>Influenza A2009 H1N1</td><td rowspan=1 colspan=1>InfluenzaB</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Denver/1/57 (H1N1)</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>.</td></tr><tr><td rowspan=1 colspan=1>Influenza A/NewYork/55/2004 (H1N1)</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>.</td><td rowspan=1 colspan=1>.</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Mal/302/54 (H1N1)</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>.</td><td rowspan=1 colspan=1>.</td></tr><tr><td rowspan=1 colspan=1>Influenza A/New Jersey/8/76 (H1Nl)</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/NWS/33 (H1N1)</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>.</td></tr><tr><td rowspan=1 colspan=1>Influenza A/PR/8/34(HINI)</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>+ ·</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/Taiwan/42/06 (H1N1)</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/WS/33 (H1N1)a</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/Swine/1976/31 (SwineHIN1</td><td rowspan=1 colspan=1>500 PFU/mLa</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/Swine/lowa/15/30 (SwineHIN1)</td><td rowspan=1 colspan=1>500 PFU/mL</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/Brisbane/59/07 (HIN1)a</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/NewCalendonia/20/1999(H1N1)&quot;</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>*</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/Victoria/3/75 (H3N2)</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>+ .</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

# CONFIDENTIAL

<table><tr><td rowspan=1 colspan=1>Viral Strain</td><td rowspan=1 colspan=1>Concentration(TCID50/mL)</td><td rowspan=1 colspan=1>InfluenzaA</td><td rowspan=1 colspan=1>Influenza A2009 HIN1</td><td rowspan=1 colspan=1>InfluenzaB</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Aichi2/68 (H3N2)</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/Hong Kong/8/68 (H3N2)</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>.</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/Hawaii/15/2001 (H3N2)</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/Port Chalmers/1/73 (H3N2)</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/Brisbane/10/07 (H3N2)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/Wisconsin/67/05 (H3N2)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/SwineNY/01/2009(2009 H1N1)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/SwineNY/02/2009(2009 H1N1)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/SwineNY/03/2009(2009 H1N1)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/California/4/2009(2009 H1N1)</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/Canada/6294(2009 H1N1)</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/WI/929-S1(2009 H1N1)</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/Mallard/WI/34/75 (H5N2)</td><td rowspan=1 colspan=1>3 pg/μLb</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Anhui/02/2005/PR8-IBCDC-RG5 (H5N1)</td><td rowspan=1 colspan=1>0.122 pg/μLb</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A/chicken/NJ/15086-3/94(H7N3)</td><td rowspan=1 colspan=1>5 pg/μLb</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza B/Allen/45</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>•</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Florida/02/06</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Florida/04/06</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>.</td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Florida/07/04</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>.</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Influenza B/GL/1739/54</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>.</td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Hong Kong/5/72</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Lee/40</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>.</td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Malaysia/2506/04</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>.</td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Maryland/1/59</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr></table>

# CONFIDENTIAL

<table><tr><td rowspan=1 colspan=1>Viral Strain</td><td rowspan=1 colspan=1>Concentration(TCID50/mL)</td><td rowspan=1 colspan=1>InfluenzaA</td><td rowspan=1 colspan=1>Influenza A2009 H1N1</td><td rowspan=1 colspan=1>InfluenzaB</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Panama/45/90</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Taiwan/2/62</td><td rowspan=1 colspan=1>50 CEID50/mL</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td></tr></table>

Concentration expressed as PFU/mL Concntration expressed in picograms $\mu \mathrm { L } ^ { \circ }$ Concentration expressed as $\mathrm { C E I D } _ { \mathsf { S } \mathsf { 0 } } / \mathsf { m L }$

# Analytical Sensitivity

# Limit of Detection

Studies were performed to determine the analytical limit of detection (LoD) of two seasonal influenza A (H1N1), two seasonal influenza A (H3N2), five influenza A 2009 H1N1 and two influenza B strains diluted into a surrogate nasopharyngeal matrix, containing human blood, mucin and sodium chloride. The LoD is defined as the lowest concentration (tissue culture infective dose $[ \mathrm { T C I D } ] _ { 5 0 } / \mathrm { m L } ,$ per sample that can be reproducibly distinguished from negative samples with $9 5 \%$ confidence or the lowest concentration at which 19 of 20 replicates were positive. Each strain was tested in replicates of 20 per concentration of virus.

The LoD was determined empirically as the first concentration that had 19/20 or 20/20 positive results. The LoD values for each strain tested are summarized in Tables 5.3 - 5.6.

Table 5.3: Confirmed LoD $\bf ( T C I D _ { 5 0 } / m L )$ - Seasonal Influenza A H1N1   

<table><tr><td rowspan=1 colspan=1>Strain ID - Influenza Asubtype H1N1</td><td rowspan=1 colspan=1>Confirmed LoD(TCID50/mL)(at least 19/20 positive)</td></tr><tr><td rowspan=1 colspan=1>Influenza A/H1/Brisbane/59/07</td><td rowspan=1 colspan=1>5 (20/20)</td></tr><tr><td rowspan=1 colspan=1>Influenza A/H1/NewCalendonia/20/1999</td><td rowspan=1 colspan=1>25 (20/20)</td></tr></table>

Table 5.4: Confirmed LoD $\mathbf { ( T C I D _ { 5 0 } / m L ) }$ - Seasonal Influenza A H3N2   

<table><tr><td rowspan=1 colspan=1>Strain ID - Influenza Asubtype H3N2</td><td rowspan=1 colspan=1>Confirmed LOD(TCID50/mL) (at least 19/20 positive)</td></tr><tr><td rowspan=1 colspan=1>Influenza A/H3/Brisbane/10/07</td><td rowspan=1 colspan=1>2.5 (19/20)</td></tr><tr><td rowspan=1 colspan=1>InfluenzaA/H3/Wisconsin/67/05</td><td rowspan=1 colspan=1>10 (20/20)</td></tr></table>

Table 5.5: Confirmed LoD $\bf ( T C I D _ { 5 0 } / m L $ - Influenza A 2009 H1N1   

<table><tr><td rowspan=1 colspan=1>Strain ID - Influenza Asubtype 2009 H1N1</td><td rowspan=1 colspan=1>Confirmed LOD(TCID50/mL) (at least 19/20 positive)</td></tr><tr><td rowspan=1 colspan=1>Influenza A/SwineNY/01/2009</td><td rowspan=1 colspan=1>1 (19/20)</td></tr><tr><td rowspan=1 colspan=1>Influenza A/SwineNY/02/2009</td><td rowspan=1 colspan=1>5 (19/20)</td></tr><tr><td rowspan=1 colspan=1>Influenza A/SwineNY/03/2009</td><td rowspan=1 colspan=1>3.5 (20/20)</td></tr><tr><td rowspan=1 colspan=1>Influenza A/Canada/6294</td><td rowspan=1 colspan=1>100 (20/20)</td></tr><tr><td rowspan=1 colspan=1>Influenza A/WI/629-S1/2009</td><td rowspan=1 colspan=1>20 (20/20)</td></tr></table>

Table 5.6: Confirmed LoD $\bf ( T C I D _ { 5 0 } / m L )$ - Influenza B   

<table><tr><td rowspan=1 colspan=1>Strain ID - Influenza B</td><td rowspan=1 colspan=1>Confirmed LOD(TCID50/mL) (at least 19/20 positive)</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Florida/02/06</td><td rowspan=1 colspan=1>2 (19/19)</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Florida/07/04</td><td rowspan=1 colspan=1>75 (20/20)</td></tr></table>

# Analytical Specificity (Exclusivity)

The analytical specificity of the Xpert Flu Assay was evaluated by testing a panel of 40 cultures consisting of 18 viral, 21 bacterial, and one yeast representing common respiratory pathogens or those potentially encountered in the nasopharynx. Three replicates of each bacterial and yeast strains were tested at concentrations $\ge 1 0 ^ { 6 } \mathrm { C F U / m L }$ . Three replicates of each virus were tested at concentrations ${ \geq } 1 0 ^ { 4 }$ $\mathrm { \ C I D } _ { 5 0 } / \mathrm { m L }$ . Purified nucleic acids (genome copies/mL) were tested for one virus strain (Cytomegalovirus) and two bacterial strains (Bordetella pertussis and Haemophilus influenzae). Positive and negative controls were included in the study. The analytical specificity was $100 \%$ . Results are shown in Table 5.7.

Table 5.7: Analytical Specificity of Xpert Flu Assay   

<table><tr><td colspan="1" rowspan="1">Strain</td><td colspan="1" rowspan="1">Concentration(per Cartridge)</td><td colspan="1" rowspan="1">InfluenzaA</td><td colspan="1" rowspan="1">Influenza A2009 H1N1</td><td colspan="1" rowspan="1">InfluenzaB</td></tr><tr><td colspan="1" rowspan="1">Positive Control 1 - InfluenzaA/influenza B</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">+</td></tr><tr><td colspan="1" rowspan="1">Positive Control 2 - Influenza A2009 HIN1</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Negative Control</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Adenovirus Type 7A</td><td colspan="1" rowspan="1">1x106 TCIDs0/mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Adenovirus Type 1</td><td colspan="1" rowspan="1">1x106 TCID50/mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Human Coronavirus 229E</td><td colspan="1" rowspan="1">1x106 TCID50/mL</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Human Coronavirus OC43</td><td colspan="1" rowspan="1">1x104 TCID50/mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirusb</td><td colspan="1" rowspan="1">1x10 Copies /mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Enterovirus Type 71</td><td colspan="1" rowspan="1">1x106 TCIDs/mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Epstein-Barr Virus</td><td colspan="1" rowspan="1">1x10 TCID5/mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Parainfluenzavirus Type 1</td><td colspan="1" rowspan="1">1x10^ TCID50/mL</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Parainfluenzavirus Type 2</td><td colspan="1" rowspan="1">1x10 TCID50/mL</td><td colspan="1" rowspan="1">•</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Parainfluenzavirus Type 3</td><td colspan="1" rowspan="1">1x10 TCIDs0/mL</td><td colspan="1" rowspan="1">•</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Measles Virus</td><td colspan="1" rowspan="1">1x10^ TCIDs/mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Human Metapneumovirus</td><td colspan="1" rowspan="1">$xi0^6 TCIDs0/mL</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Mumps Virus</td><td colspan="1" rowspan="1">1x106 TCIDsg/mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Respiratory Syncytial Virus A</td><td colspan="1" rowspan="1">1x10^ TCIDs/mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Respiratory Syncytial Virus B</td><td colspan="1" rowspan="1">1x10 TCIDs/mL</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Human HSV Type 1</td><td colspan="1" rowspan="1">1x106 TCID50/mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Human Rhinovirus Type 4</td><td colspan="1" rowspan="1">1x106 TCIDs/mL</td><td colspan="1" rowspan="1">.</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Echovirus 11</td><td colspan="1" rowspan="1">1x106 TCIDso/mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Bordetella pertussis</td><td colspan="1" rowspan="1">1x106 $Copies/mL</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Chlamydia pneumoniae</td><td colspan="1" rowspan="1">1x106CFU/mL</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Corynebacterium xerosis</td><td colspan="1" rowspan="1">1x10CFU/mL</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">1x10CFU/mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Proteus vulgaris</td><td colspan="1" rowspan="1">1x106CFU/mL</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Proteus mirabilis</td><td colspan="1" rowspan="1">1x10CFU/mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">1x106CFU/mL</td><td colspan="1" rowspan="1">*</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Haemophilus influenzae</td><td colspan="1" rowspan="1">1x106 Copies/mL</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Lactobacillus crispatus</td><td colspan="1" rowspan="1">1x10CFU/mL</td><td colspan="1" rowspan="1">•</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Legionella pneumophila</td><td colspan="1" rowspan="1">1x10CFU/mL</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">•</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Moraxella catarrhalis</td><td colspan="1" rowspan="1">1x106CFU/mL</td><td colspan="1" rowspan="1">•</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Mycobacterium tuberculosis(BCG strain)</td><td colspan="1" rowspan="1">1x10CFU/mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Mycoplasma pneumoniae</td><td colspan="1" rowspan="1">1x106CFU/mL</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Neisseria meningitides</td><td colspan="1" rowspan="1">1x106CFU/mL</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Neisseria Cinneria</td><td colspan="1" rowspan="1">1x106CFU/mL</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td><td colspan="1" rowspan="1">1x106CFU/mL</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Staphylococcus aureus</td><td colspan="1" rowspan="1">1x106CFU/mL</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Staphylococcus epidermidis</td><td colspan="1" rowspan="1">1x10CFU/mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Streptococcus pneumoniae</td><td colspan="1" rowspan="1">1x10CFU/mL</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Streptococcus pyogenes</td><td colspan="1" rowspan="1">1x10CFU/mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Streptococcus salivarius</td><td colspan="1" rowspan="1">1x10CFU/mL</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td></tr><tr><td colspan="1" rowspan="1">Candida albicans</td><td colspan="1" rowspan="1">1x10CFU/mL</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1">-</td><td colspan="1" rowspan="1"></td></tr></table>

"Cross-reactivity with other swine-origin strains was not evaluated.   
bNucleic acid was tested for Cytomegalovirus, Bordetella pertussis, and Haemophilus influenzae.

# Interfering Substances

In a non-clinical study, potentially interfering substances that may be present in the nasopharynx were evaluated directly relative to the performance of the Xpert Flu Assay. Potentially interfering exogenous substances in the nasopharynx may include, but are not limited to: blood, nasal secretions or mucus, and nasal and throat medications used to relieve congestion, nasal dryness, irritation, or asthma and allergy symptoms. These substances are listed in Table 5.8 with active ingredients and concentrations tested shown. Highly viscous samples, resulting from the addition of $1 . 5 \% \mathrm { ( w / v ) }$ and $2 . 5 \%$ (w/v) mucin yielded false negative test results from the Xpert Flu Assay. Inhibition of the Xpert Flu Assay was also observed from the addition of $1 \%$ (w/v) mucin, resulting in delayed detection of influenza A, influenza A subtype $2 0 0 9 \mathrm { H } 1 \mathrm { N } 1$ and influenza B.

Table 5.8: Potentially Interfering Substances in Xpert Flu Assay.   

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Description/Active Ingredient</td><td rowspan=1 colspan=1>Concentration Tested</td></tr><tr><td rowspan=1 colspan=1>Blood (human)</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>2%(v/v)</td></tr><tr><td rowspan=1 colspan=1>Mucin</td><td rowspan=1 colspan=1>Purified mucin protein (Bovine orporcine submaxillary gland)</td><td rowspan=1 colspan=1>2.5%, 1.5%, 1% and0.5% (w/v)</td></tr><tr><td rowspan=1 colspan=1>Neo-Synephrine®Nasal Drops</td><td rowspan=1 colspan=1>Phenylephrine HCI</td><td rowspan=1 colspan=1>15% (v/v)</td></tr><tr><td rowspan=1 colspan=1>Anefrin NasalSpray</td><td rowspan=1 colspan=1>Oxymetazoline Hydrochloride</td><td rowspan=1 colspan=1>15% (v/v)</td></tr><tr><td rowspan=1 colspan=1>Zicam® NasalGel</td><td rowspan=1 colspan=1>Luffa opperculata, Galphimia glauca,Histaminum hydrochloricum Sulfur</td><td rowspan=1 colspan=1>5% (v/v)</td></tr><tr><td rowspan=1 colspan=1>Saline NasalSpray</td><td rowspan=1 colspan=1>Sodium Chloride with preservatives</td><td rowspan=1 colspan=1>15% (v/v)</td></tr><tr><td rowspan=1 colspan=1>Antibiotic,nasal ointment</td><td rowspan=1 colspan=1>Mupirocin</td><td rowspan=1 colspan=1>10 mg/mL</td></tr><tr><td rowspan=1 colspan=1>Antibacterial,systemic</td><td rowspan=1 colspan=1>Tobramycin</td><td rowspan=1 colspan=1>4.0 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Throatlozenges, oralanesthetic andanalgesic</td><td rowspan=1 colspan=1>Menthol</td><td rowspan=1 colspan=1>1.7 mg/mL menthol</td></tr></table>

# Carry-Over Contamination Study

A study was conducted to demonstrate that single-use, self-contained GeneXpert cartridges prevent carry-over contamination in negative samples run following very high positive samples in the same GeneXpert module. The study consisted of a negative sample processed in the same GeneXpert module immediately following a very high influenza A subtype 2009 H1N1 sample (approximately $1 0 ^ { 6 } \dot { \mathrm { T C I D } } _ { 5 0 } / \mathrm { t e s t } \dot { \mathrm { t } }$ or influenza B sample (approximately $1 0 ^ { 6 } \mathrm { T C I D } _ { 5 0 } / \mathrm { t e s t } )$ .This testing scheme was repeated 20 times on four GeneXpert modules for a total of 88 runs resulting in 40 positive and 48 negative specimens. All 40 positive samples were correctly reported as influenza A 2009 H1N1 positive or influenza B positive. All 48 negative samples were correctly reported as Flu A negative, 2009 H1N1 not detected and Flu B negative.

# Linearity

A study was conducted to define the reportable range of the Xpert Flu Assay and demonstrate a linear relationship between target input and assay output. Linearity was evaluated using two seasonal influenza A H1N1, two seasonal influenza A H3N2, two influenza A 2009 H1N1, and two influenza B strains diluted over four to five logs and processed using the Xpert Flu Assay. Replicates of 4 were tested.

Under the conditions of the study, the Xpert Flu Assay responds linearly over six logs for seasonal influenza A H1N1, seasonal influenza A H3N2 and influenza A 2009 H1N1; and over 5 logs for influenza B strains tested.

# Reproducibility

A panel of 10 specimens with varying concentrations of influenza A, influenza B, and influenza A subtype 2009 H1N1 were tested in duplicate on 10 different days at each of three sites (10 specimens x 2 times/ day x 10 days x 3 sites). One lot of Xpert Flu Assay was used at each of the 3 testing sites. Xpert Flu Assays were performed according to the Xpert Flu Assay procedure. Results are summarized in Table 5.9.

Table 5.9: Summary of Reproducibility Results   

<table><tr><td rowspan=1 colspan=1>Sample ID</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>% Total Agreementby Sample</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(60/60)</td></tr><tr><td rowspan=1 colspan=1>Flu Amoderate positive</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(19/19)a</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(59/59)</td></tr><tr><td rowspan=1 colspan=1>Flu Alow positive</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(60/60)</td></tr><tr><td rowspan=1 colspan=1>Flu Ahigh negative</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>95.0%(19/20)</td><td rowspan=1 colspan=1>90.0%(18/20)</td><td rowspan=1 colspan=1>95.0%(57/60)</td></tr><tr><td rowspan=1 colspan=1>2009 H1N1moderate positive</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(60/60)</td></tr><tr><td rowspan=1 colspan=1>2009 H1N1low positive</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(19/19)b</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(59/59)</td></tr></table>

# CONFIDENTIAL

<table><tr><td rowspan=1 colspan=1>Sample ID</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>Site 2:</td><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>% Total Agreementby Sample</td></tr><tr><td rowspan=1 colspan=1>2009 H1N1high negative</td><td rowspan=1 colspan=1>94.7%(18/19)a</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>89.5%(17/19)a</td><td rowspan=1 colspan=1>94.8%(55/58)c</td></tr><tr><td rowspan=1 colspan=1>Flu Bmoderate positive</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(60/60)</td></tr><tr><td rowspan=1 colspan=1>Flu Blow positive</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(20/20)</td><td rowspan=1 colspan=1>100%(60/60)</td></tr><tr><td rowspan=1 colspan=1>Flu Bhigh negative</td><td rowspan=1 colspan=1>90.0%(18/20)</td><td rowspan=1 colspan=1>95.0%(19/20)</td><td rowspan=1 colspan=1>55.0%(11/20)</td><td rowspan=1 colspan=1>80.0%(48/60)</td></tr><tr><td rowspan=1 colspan=1>% Total Agreement</td><td rowspan=1 colspan=1>98.5%%(196/199)</td><td rowspan=1 colspan=1>99.0%(196/198)</td><td rowspan=1 colspan=1>93.5%(186/199)</td><td rowspan=1 colspan=1>97.0%(578/596)</td></tr></table>

EPY $\mathfrak { a } _ { \mathfrak { n } = 1 9 }$ because repeat yielded indeterminate result. EY $\mathfrak { d } _ { \mathfrak { n } = 1 9 }$ because one sample was indeterminate and not retested. ${ \mathfrak { c } } _ { 9 / 5 5 }$ samples negative for 2009 H1N1 resulted in a valid Flu A positive call, as the Flu A signal was detected. A valid $2 0 0 9 \mathrm { H } 1 \mathrm { N } |$ positive call requires detection of both the Flu A and 2009 H1N1 signals.

# Instrument System Reproducibility

An in-house reproducibility study was conducted to compare the performance of the GeneXpert Dx and the Infinity instrument systems. A panel of 10 specimens with varying concentrations of influenza A, influenza B, and influenza A subtype 2009 H1N1 were tested in duplicate on 12 different days by two operators. Each operator conducted four runs of each panel specimen per day on each of the two instrument systems (1 1 specimens $\mathbf { x } \ : 2$ times/ day x 12 days x 2 operators x 2 instrument systems). One lot of Xpert Flu Assay was used for the study. Xpert Flu Assays were performed according to the Xpert Flu Assay procedure. Results are summarized in Table 5.10.

Table 5.10: Summary of Instrument System Reproducibility Results   

<table><tr><td rowspan=1 colspan=1>Sample ID</td><td rowspan=1 colspan=1>GeneXpert Dx</td><td rowspan=1 colspan=1>Infinity</td><td rowspan=1 colspan=1>% Total Agreementby Sample</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>100.0%(96/96)</td><td rowspan=1 colspan=1>100.0%(96/96)</td><td rowspan=1 colspan=1>100.0%(192/192)</td></tr><tr><td rowspan=1 colspan=1>Flu Amoderate positive</td><td rowspan=1 colspan=1>100.0%(96/96)</td><td rowspan=1 colspan=1>100.0%(96/96)</td><td rowspan=1 colspan=1>100.0%(192/192)</td></tr><tr><td rowspan=1 colspan=1>Flu Alow positive</td><td rowspan=1 colspan=1>100.0%(96/96)</td><td rowspan=1 colspan=1>100.0%(96/96)</td><td rowspan=1 colspan=1>100.0%(192/192)</td></tr><tr><td rowspan=1 colspan=1>Flu Ahigh negative</td><td rowspan=1 colspan=1>89.6%(86/96)</td><td rowspan=1 colspan=1>86.5%(83/96)</td><td rowspan=1 colspan=1>88.0%(169/192)</td></tr><tr><td rowspan=1 colspan=1>2009 H1N1moderate positive</td><td rowspan=1 colspan=1>100.0%(96/96)</td><td rowspan=1 colspan=1>100.0%(96/96)</td><td rowspan=1 colspan=1>100.0%(192/192)</td></tr><tr><td rowspan=1 colspan=1>2009 H1N1low positive</td><td rowspan=1 colspan=1>100.0%(96/96)</td><td rowspan=1 colspan=1>100.0%(96/96)</td><td rowspan=1 colspan=1>100.0%(192/192)</td></tr><tr><td rowspan=1 colspan=1>2009 H1N1high negative</td><td rowspan=1 colspan=1>84.4%(81/96)</td><td rowspan=1 colspan=1>92.6%(88/95)a</td><td rowspan=1 colspan=1>88.5%(169/191)</td></tr><tr><td rowspan=1 colspan=1>Flu Bmoderate positive</td><td rowspan=1 colspan=1>100.0%(96/96)</td><td rowspan=1 colspan=1>100.0%(96/96)</td><td rowspan=1 colspan=1>100.0%(192/192)</td></tr></table>

# CONFIDENTIAL

<table><tr><td rowspan=1 colspan=1>Sample ID</td><td rowspan=1 colspan=1>GeneXpert Dx</td><td rowspan=1 colspan=1>Infinity</td><td rowspan=1 colspan=1>% Total Agreementby Sample</td></tr><tr><td rowspan=1 colspan=1>Flu Blow positive</td><td rowspan=1 colspan=1>100.0%(96/96)</td><td rowspan=1 colspan=1>100.0%(96/96)</td><td rowspan=1 colspan=1>100.0%(192/192)</td></tr><tr><td rowspan=1 colspan=1>Flu Bhigh negative</td><td rowspan=1 colspan=1>87.5%(84/96)</td><td rowspan=1 colspan=1>82.3%(79/96)</td><td rowspan=1 colspan=1>84.9%(163/192)</td></tr><tr><td rowspan=1 colspan=1>% Total Agreement</td><td rowspan=1 colspan=1>96.1%(923/960)</td><td rowspan=1 colspan=1>96.1%(922/959)</td><td rowspan=1 colspan=1>96.1%(1845/1919)</td></tr></table>

$\widetilde { \mathfrak { a } } _ { \mathfrak { n } = 9 5 }$ because repeat yielded indeterminate result.

# Clinical Performance Characteristics

# Clinical Performance Study

Performance characteristics of the Xpert Flu Assay on prospective and archived specimens were evaluated at six institutions in the U.S. and Australia. Due to the low prevalence of influenza viruses and the difficulty in obtaining fresh influenza-positive specimens, the specimen population for this study was supplemented with frozen archived specimens.

Subjects included individuals whose routine care called for collection of NA/W or NP swab specimens for influenza testing. For eligible subjects, aliquots of leftover sample were obtained for testing with the Xpert Flu Assay and reference testing, and patient management continued at the site per the standard practice.

The Xpert Flu Assay performance was compared to viral culture followed by direct fluorescent assay (DFA). Sequencing was performed for all influenza A positive specimens. For archived specimens, where viral culture was not performed prior to freezing, a FDA cleared molecular assay was performed as the comparator assay. Samples included nasal NA/W and NP swab specimens collected for routine testing from patients suspected of influenza infection.

Overall Results Prospective Specimens

A total of 342 prospective NA/W specimens were tested for influenza A, influenza A subtype 2009 H1N1 and influenza B by the Xpert Flu Assay and viral culture plus DFA. A total of 297 prospectively collected NP swab specimens were tested for influenza A, influenza A subtype 2009 H1N1 and influenza B by the Xpert Flu Assay and viral culture plus DFA. All influenza A positive specimens, identified by viral culture/DFA, were sequenced to differentiate influenza A subtype 2009 H1N1 from other influenza A subtypes

On fresh, prospective NA/W specimens, the Xpert Flu Assay demonstrated a sensitivity and specificity for detection of influenza A of $8 5 . 7 \%$ and $9 9 . 1 \%$ , respectively, relative to viral culture plus DFA, with sequence confirmation of all influenza A positive viral isolates, or specimens in transport medium if isolates were not available (Table 5.11).

The Xpert Flu Assay sensitivity and specificity for influenza A subtype 2009 H1N1 with NA/W specimens were $100 \%$ and $9 8 . 8 \%$ , respectively (Table 5.12). The Xpert Flu Assay sensitivity and specificity for influenza B with NA/W specimens were $100 \%$ and $9 9 . 4 \%$ , respectively (Table 5.13).

Table 5.11: Xpert Flu Assay Performance on Prospective NA/W Specimens: Influenza A   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Culture/DFA</td></tr><tr><td rowspan=4 colspan=1>Sue Rd ResE</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>.6</td><td rowspan=1 colspan=1>3a$</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1b</td><td rowspan=1 colspan=1>332</td><td rowspan=1 colspan=1>333</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>335      •</td><td rowspan=1 colspan=1>342</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Sensitivity:Specificity:</td><td rowspan=1 colspan=2>85.7% (95% CI: 42.1-99.6)99.1% (95% CI: 97.4-99.8)</td></tr></table>

\*Testing results by sequencing: 3 of 3 were H1N1. bTesting results by sequencing: Flu A

Table 5.12: Xpert Flu Assay Performance on Prospective NA/W Specimens: Influenza A, 2009 H1N1   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Culture/DFA &amp; Sequencing</td></tr><tr><td rowspan=4 colspan=1>Se R esE</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4a</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>334</td><td rowspan=1 colspan=1>334</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>338</td><td rowspan=1 colspan=1>342</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Sensitivity:Specificity:</td><td rowspan=1 colspan=2>100% (95%6 CI: 39.8-100)98.8% (95% CI: 97.0-99.7)</td></tr></table>

aTesting results by sequencing: 3 of 4 were H1N1; 1 of 4 was Flu A.

# CONFIDENTIAL

Table 5.13: Xpert Flu Assay Performance on Prospective NA/W Specimens: Influenza B   

<table><tr><td rowspan=1 colspan=1>.</td><td rowspan=1 colspan=4>Culture/DFA</td></tr><tr><td rowspan=4 colspan=1>Sees n edX</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>2a</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>333</td><td rowspan=1 colspan=1>333</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>335</td><td rowspan=1 colspan=1>342</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Sensitivity:Specificity:</td><td rowspan=1 colspan=2>100% (95% CI: 65.2-100)99.4% (95% CI: 98.1-99.9)</td></tr></table>

Testing results by sequencing: 2 of 2 were Flu B.

On prospectively collected NP swabs, the Xpert Flu Assay demonstrated a sensitivity and specificity for detection of influenza A of $100 \%$ and $9 8 . 3 \%$ , respectively, relative to viral culture plus DFA, with sequence confirmation of all influenza A positive viral isolates, or specimens in transport medium if isolates were not available (Table 5.14). The Xpert Flu Assay sensitivity and specificity for influenza A subtype 2009 H1N1 with NP swabs were $100 \%$ and $9 9 . 0 \%$ , respectively (Table 5.15). The Xpert Flu Assay sensitivity and specificity for influenza B with NP swabs were $8 7 . 5 \%$ and $9 9 . 7 \%$ , respectively (Table 5.16).

Table 5.14: Xpert Flu Assay Performance on Prospective NP Swab Specimens: Influenza A   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Culture/DFA</td></tr><tr><td rowspan=4 colspan=1>See R PeX</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>5$</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>285</td><td rowspan=1 colspan=1>285</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>290</td><td rowspan=1 colspan=1>297</td></tr><tr><td rowspan=1 colspan=1>→</td><td rowspan=1 colspan=2>Sensitivity:Specificity:</td><td rowspan=1 colspan=2>100% (95% CI: 59.0-100)98.3% (95% CI: 96.0-99.4)</td></tr></table>

Testing results by sequencing: 3 of 5 were H1N1; 2 of 5 were Flu A.

# CONFIDENTIAL

Table 5.15: Xpert Flu Assay Performance on Prospective NP Swab Specimens: Influenza A, 2009 H1N1   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Culture/DFA &amp; Sequencing</td></tr><tr><td rowspan=4 colspan=1>Sess R FesX</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>3a</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>289</td><td rowspan=1 colspan=1>289</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>292</td><td rowspan=1 colspan=1>297</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Sensitivity:Specificity:</td><td rowspan=1 colspan=2>100% (95% CI: 47.8-100)99.0% (95% CI: 97.0-99.8)</td></tr></table>

Testing results by sequencing: 2 of 3 were H1N1; 1 of 3 was Flu A.

Table 5.16: Xpert Flu Assay Performance on Prospective NP Swab Specimens: Influenza B   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Culture/DFA</td></tr><tr><td rowspan=4 colspan=1>See  fesE</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>1a</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1b</td><td rowspan=1 colspan=1>288</td><td rowspan=1 colspan=1>289</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>289</td><td rowspan=1 colspan=1>297</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Sensitivity:Specificity:</td><td rowspan=1 colspan=2>87.5% (95% CI: 47.3-99.7)99.7% (95% CI: 98.1-100)</td></tr></table>

Testing results by sequencing: Flu B. en esult  equencing Flu A.

# Archived Specimens

A total of 425 archived NA/W specimens were tested for influenza A, influenza A subtype 2009 H1N1 and influenza B by the Xpert Flu Assay and a FDA cleared molecular comparator device. A total of 150 archived NP swab specimens were tested for influenza A, influenza A subtype 2009 H1N1 and influenza B by the Xpert Flu Assay and viral culture plus DFA; 177 archived NP swab specimens did not have viral culture results available and were tested by the FDA cleared molecular comparator device. All influenza A positive specimens indentified by viral culture/DFA or cleared molecular comparator device were sequenced to differentiate influenza A subtype 2009 H1N1 from other influenza A subtypes.

On archived NA/W specimens, the Xpert Flu Assay demonstrated a positive and negative agreement for detection of influenza A of $9 9 . 4 \%$ and $100 \%$ , respectively, relative to viral culture plus DFA, with sequence confirmation of all influenza A positive viral isolates, or specimens in transport medium if isolates were not available (Table 5.17). The Xpert Flu Assay positive and negative agreement for influenza A subtype $2 0 0 9 \mathrm { H } 1 \dot { \mathrm { N } } 1$ with NA/W specimens were $9 8 . 4 \%$ and $9 9 . 7 \%$ (Table 5.18). The Xpert Flu Assay positive and negative agreement for influenza B with NA/W specimens were $100 \%$ and $100 \%$ respectively (Table 5.19)

Table 5.17: Xpert Flu Assay Performance on Archived NA/W Specimens: Influenza A   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>FDA Cleared Molecular Comparator</td></tr><tr><td rowspan=4 colspan=1>See R BsE</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>159</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>159</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1&quot;</td><td rowspan=1 colspan=1>265</td><td rowspan=1 colspan=1>266</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>160</td><td rowspan=1 colspan=1>265</td><td rowspan=1 colspan=1>425</td></tr><tr><td rowspan=1 colspan=1>→</td><td rowspan=1 colspan=2>Positive Agreement:Negative Agreement:</td><td rowspan=1 colspan=2>99.4% (95% CI: 96.6-100)100% (95% CI: 98.6-100)</td></tr></table>

Testing by sequencing: no sequence match for Flu A, H1N1 or Flu B

Table 5.18: Xpert Flu Assay Performance on Archived NA/W Specimens: Influenza A, 2009 H1N1   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>FDA Cleared Molecular Comparator &amp; Sequencing</td></tr><tr><td rowspan=4 colspan=1>Se R ResX</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>124</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>125</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>2b</td><td rowspan=1 colspan=1>\295</td><td rowspan=1 colspan=1>297</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>126</td><td rowspan=1 colspan=1>296</td><td rowspan=1 colspan=1>422c</td></tr><tr><td rowspan=1 colspan=1>→</td><td rowspan=1 colspan=2>Positive Agreement:Negative Agreement:</td><td rowspan=1 colspan=2>98.4% (95% CI: 94.4-99.8)99.7% (95% CI: 98.1-100)</td></tr></table>

\*Testing results by sequencing: Flu A, not H1Nl. Testing results by sequencing: 2 of 2 HIN. $^ { \mathfrak { s } } 3$ samples excluded due to PHRED score $\mathtt { < } 2 0$ .

# CONFIDENTIAL

Table 5.19: Xpert Flu Assay Performance on Archived NA/W Specimens: Influenza B   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>FDA Cleared Molecular Comparator</td></tr><tr><td rowspan=4 colspan=1>Sess nd ReX</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>385</td><td rowspan=1 colspan=1>385</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>385</td><td rowspan=1 colspan=1>425</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Positive Agreement:Negative Agreement:</td><td rowspan=1 colspan=2>100% (95% CI: 91.2-100)100% (95% CI: 99.0-100)</td></tr></table>

On archived NP swabs, the Xpert Flu Assay demonstrated a positive and negative agreement for detection of influenza A of $9 7 . 5 \%$ and $100 \%$ , respectively, relative to viral culture plus DFA, with sequence confirmation of all influenza A positive viral isolates, or specimens in transport medium if isolates were not available (Table 5.20). The Xpert Flu Assay positive and negative agreement for influenza A subtype 2009 H1N1 with NP swabs were $100 \%$ and $100 \%$ , respectively (Table 5.21). The Xpert Flu Assay positive and negative for influenza B with NP swabs were $9 3 . 8 \%$ and $9 9 . 2 \%$ , respectively (Table 5.22).

Table 5.20: Xpert Flu Assay Performance vs. Comparator Method with NP Swab Specimens: Influenza A   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Culture/DFA</td></tr><tr><td rowspan=4 colspan=1>Se  X</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>115</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>115</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>3a</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>35</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>150</td></tr><tr><td rowspan=1 colspan=1>→</td><td rowspan=1 colspan=2>Positive Agreement:Negative Agreement:</td><td rowspan=1 colspan=2>97.5% (95% CI: 92.7-99.5)100% (95% CI: 89.1-100)</td></tr></table>

Tetig results by sequencing   3 were o sequence match or Flu A, H, r Flu B; 1 of 3 was Flu B.

Table 5.21: Xpert Flu Assay Performance vs. Comparator Method with NP Swab Specimens: 2009 H1N1   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Culture/DFA &amp; Sequencing</td></tr><tr><td rowspan=4 colspan=1>See R sE</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>84</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>65</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>149a</td></tr><tr><td rowspan=1 colspan=1>→</td><td rowspan=1 colspan=2>Positive Agreement:Negative Agreement:</td><td rowspan=1 colspan=2>100% (95% CI: 95.7-100)100% (95% CI: 94.5-100)</td></tr></table>

One sample excluded due to PHRED score $\mathtt { < } 2 0$ .

Table 5.22: Xpert Flu Assay Performance vs. Comparator Method with NP SwabSpecimens: Influenza B   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Culture/DFA</td></tr><tr><td rowspan=4 colspan=1>Se  kX</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>1a</td><td rowspan=1 colspan=1>31</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>2b</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>119</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>150</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Positive Agreement:Negative Agreement:</td><td rowspan=1 colspan=2>93.8% (95% CI: 79.2-99.2)99.2% (95% CI: 95.4-100)</td></tr></table>

Testing results by sequencing: Flu B. bTesting results by sequencing: no sequence match for Flu A, H1N1 or Flu B.

On archived NP swabs, the Xpert Flu Assay demonstrated a positive agreement and negative agreement for detection of influenza A of $9 8 . 1 \%$ and $9 9 . 2 \%$ , respectively, relative to the comparator assay, with sequence confirmation of all influenza A positive viral isolates, or specimens in transport medium if isolates were not available (Table 5.23). The Xpert Flu Assay positive and negative agreement for influenza A subtype 2009 H1N1 with NP swabs were $100 \%$ and $9 9 . 3 \%$ , respectively (Table 5.24). The Xpert Flu Assay positive and negative agreements for influenza B with NP swabs were $9 3 . 8 \%$ EY and $100 \%$ , respectively (Table 5.25).

Table 5.23: Xpert Flu Assay Performance on Archived NP Swab Specimens: Influenza A   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>FDA Cleared Molecular Comparator</td></tr><tr><td rowspan=4 colspan=1>Sues n sE</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>1a</td><td rowspan=1 colspan=1>52</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1b</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>121</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>173</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Positive Agreement:Negative Agreement:</td><td rowspan=1 colspan=2>98.1% (95% CI: 89.7-100)99.2% (95% CI: 95.5-100)</td></tr></table>

No test results by sequencing available.

Table 5.24: Xpert Flu Assay Performance vs. Comparator Method with NP Swab Specimens: 2009 H1N1   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>FDA Cleared Molecular Comparator &amp; Sequencing</td></tr><tr><td rowspan=4 colspan=1>Sss R fesX</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>1&quot;</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>142</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>172b</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Positive Agreement: 100% (95% CI: 88.1-100)Negative Agreement: 99.3% (95% CI: 96.2-100)</td></tr></table>

\*No test results available. bSequence confirmation not available for one sample.

Table 5.25: Xpert Flu Assay Performance vs. Comparator Method with NP Swab Specimens: Influenza B   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>FDA Cleared Molecular Comparator</td></tr><tr><td rowspan=4 colspan=1>See R ReX</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>1a</td><td rowspan=1 colspan=1>157</td><td rowspan=1 colspan=1>158</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>157</td><td rowspan=1 colspan=1>173</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=4>Positive Agreement: 93.8% (95% CI: 69.8-99.8)Negative Agreement: 100% (95% CI: 97.7-100)</td></tr></table>

$\overline { { \mathfrak { a } _ { \mathrm { N } 0 } } }$ test results by sequencing available.

# CONFIDENTIAL

Of the Xpert Flu Assays runs performed with eligible specimens, $9 7 . 1 \%$ (1351/1391) of these specimens were successful on the first attempt. The remaining 40 gave indeterminate results on the first attempt (26 ERROR, 10 INVALID and 4 NO RESULT). Thirty-six of the 40 specimens yielded valid results after a single retest; four of the specimens were indeterminate on the second attempt. The assay success rate was equivalent for archived $[ 9 6 . 8 \%$ (727/751)] and fresh $\{ 9 7 . 5 \%$ (624/640)] specimens.

# Conclusions

The results of the nonclinical analytical and clinical performance studies summarized above demonstrate that the Xpert Flu Assay is as safe and effective as the reference method, and therefore is substantially equivalent to the predicate devices.

Cepheid   
c/o Kerry J. Flom, Ph.D.   
Senior Vice President,   
Clinical Affairs and Regulatory Submissions 904 Caribbean Drive   
Sunnyvale, California 94089-1189

Re: K103766 Trade/Device Name: Xpert Flu Assay Regulation Number: 21 CFR§ 866.3980 Regulation Name: Respiratory viral panel multiplex nucleic acid assay Regulatory Class: Class II Product Code: OQW,OCC, O0I Dated: March 04, 2011 Received: March 07, 2011

Dear Dr. Flom:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section $5 1 0 ( \mathsf { k } )$ premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device rcsults in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and ple ac he O I  iasevval n Safya (0)7 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html. Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

![](images/d4d4e9b8a64dbf214dd96dceff591cddbff6ddd7769b5138da65572f9bdb8a71.jpg)

# CONFIDENTIAL

# 4.0 Indications for Use Form

510(k) Number (if known): _K103766

Device Name: Xpert@® Flu Assay

Indications for Use:

The Cepheid $\textsuperscript { \textregistered }$ Xpert Flu Assay is an automated, multiplex real-time RT-PCR assay intended for the in vitro qualitative detection and differentiation of influenza A, influenza B and 2009 H1N1 influenza viral RNA. The Xpert Flu Assay uses nasal aspirates/washes and nasopharyngeal swab specimens collected from patients with signs and symptoms of respiratory infection in conjunction with clinical and epidemiological risk factors. The Xpert Flu Assay is intended as an aid in the diagnosis of influenza.

Negative results do not preclude influenza virus infection and should not be used as the sole basis for treatment or other patient management decisions.

Performance characteristics for influenza A were established during the 2009-2010 influenza season when 2009 H1N1 influenza was the predominant influenza A virus in circulation. When other influenza A viruses are emerging, performance characteristics may vary.

If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a BSL $^ { 3 + }$ facility is available to receive and culture specimens.

<table><tr><td>Prescription Use X (Part 21 CFR 801 Subpart D)</td><td>AND/OR</td><td>Over-The-Counter Use (21 CFR 801 Subpart C)</td></tr></table>

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Saatios

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety